2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkers
2021
Newly identified chemotherapy‐induced peripheral neuropathy in a childhood cancer survivorship clinic
Rodwin RL, Ross WL, Rotatori J, Allen K, Auerbach C, Balsamo LM, Kadan‐Lottick N. Newly identified chemotherapy‐induced peripheral neuropathy in a childhood cancer survivorship clinic. Pediatric Blood & Cancer 2021, 69: e29550. PMID: 34971076, PMCID: PMC8805800, DOI: 10.1002/pbc.29550.Peer-Reviewed Original Research